Glenmark Pharmaceuticals Q1 Result: PAT at ₹482.83 Crore, Revenue at ₹4,018 Crore

Glenmark Pharmaceuticals reported a significant increase in its consolidated profit after tax (PAT), reaching ₹482.83 crore for the first quarter ending June 30, 2026. This represents strong growth compared to the same quarter last fiscal year, which recorded a PAT of ₹46.97 crore. The prior year quarter also included an exceptional expense of ₹323.23 crore, contributing to the lower PAT.

Revenue and Expense Overview

For the quarter, consolidated total revenue from operations was ₹4,018.48 crore, up from ₹3,264.44 crore in the corresponding period last year.

Total expenses increased as well, amounting to ₹3,440.86 crore compared to ₹2,872.07 crore in the previous year’s quarter.

Regional Performance Highlights

Glenmark’s Chairman and Managing Director, Glenn Saldanha, highlighted that fiscal year 2027 commenced with broad growth across key markets. This growth reflects strong execution capabilities and overall business resilience.

Key regional performances include:

• India Market: Revenue increased by 15.5% to ₹1,432.1 crore from ₹1,239.9 crore.
• North America: Revenue rose significantly to ₹1,097.4 crore from ₹778 crore, driven by new respiratory product launches.
• Europe: Revenue climbed to ₹747.2 crore from ₹667.8 crore.
• Emerging Markets: Continued strong momentum, sustaining the company’s diversified global operations.

Strategic Outlook

Mr. Saldanha emphasized that these results support Glenmark’s strategic focus on strengthening its core businesses while expanding specialty and innovation-driven platforms.

Key Takeaways

• Glenmark’s Q1 PAT surged to ₹482.83 crore from ₹46.97 crore year-over-year.
• Total revenue reached ₹4,018.48 crore, marking robust growth across markets.
• North America and India were key contributors to revenue increases.
• Expenses also rose, reflecting investment and increased operations.
• Company strategy emphasizes core business reinforcement and specialty innovation expansion.